Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Addressing the Big Question: Beyond Progressive Pulmonary Fibrosis – Are we Treating the Right Target?

3:59 pm - Tuesday 29th September 2026

Addressing the Big Question: Beyond Progressive Pulmonary Fibrosis – Are we Treating the Right Target?

Addressing the Big Question: Beyond Progressive Pulmonary Fibrosis – Are we Treating the Right Target?

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By